Sana Therapeutics snags Oscine, adding cell therapy leader Steve Goldman to its star-studded staff

Sana Biotechnology CEO Steve Harr began kicking around the idea of acquiring Oscine early on in the companies’ partnership. About a year ago, over dinner with the University of Rochester Medical Center spinout’s CEO and scientific founder, he pulled the trigger.